Valeant completes buyout of PreCision Dermatology; Novartis changes clinical trial rules;

@FiercePharma: Top-read on FP Monday: EU approves GSK's Mekinist and Novartis will reap the rewards. Article | Follow @FiercePharma

@EricPFierce: Health Canada tells GSK to get its vaccine house in order as flu season approaches. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Ackman puts forth his slate of new Allergan directors. Report | Follow @CarlyHFierce

> Valeant Pharmaceuticals ($VRX) has completed the $475 million acquisition of PreCision Dermatology. Release

> Robert J. Hombach, currently chief financial officer for Baxter International ($BAX), will become CFO of the unnamed pharmaceutical company that will be created when Baxter next year spins off its biopharma operations. Release

> The FDA has granted priority to review to Purdue Pharma's tamper-resistant competitor to Zohydro, the pain drug for which the FDA has been criticized for approving by those afraid it will be widely abused. Story

> Novartis ($NVS), which is embroiled in a controversy in Japan over the way researchers handled studies, has amended its requirements for clinical trials by outside researchers. Story

> Mylan ($MYL) has launched a generic of Boehringer Ingelheim's hypertension drug Micardis. Story

> Those on both sides of the debate over legalizing marijuana say it is unlikely the FDA, which is evaluating marijuana's place as a Schedule I drug, will downgrade its classification. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA lowers regulatory bar for neurostimulators to treat headache. Story | Follow @FierceMedDev

@StacyALawrence: Boston Scientific backs Israeli cardio device startup Mvalve with $15M. More | Follow @StacyALawrence

@VarunSaxena2: Check out our special report on the top 10 highest paid med tech CEOs. Feature | Follow @VarunSaxena2

@MichaelGFierce: A tiny, "walking" robot powered by a muscle cell? It could help deliver drugs one day. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Rapid Dx tests for Chagas disease yield quick, reliable results without lab confirmation, according to study. New York Times article | Follow @EmilyWFierce

> Researchers develop realtime, 'nanojuice'-enabled imaging method for gut. Report

> Ulthera device clears FDA for décolleté on heels of Merz acquisition plans. News

> Surgeons tout benefits of Google Glass in operating room. Article

Biotech News

@FierceBiotech: AstraZeneca spreads its virtual reach to cardio R&D with new partnership. News | Follow @FierceBiotech

@JohnCFierce: Intent on closing a deal, AbbVie boosts its bid for Shire to $51B. News | Follow @JohnCFierce

@DamianFierce: So $SHPG has 10 days to consider $ABBV's +11% offer. Press release | Follow @DamianFierce

@EmilyMFierce: European neuroscientists ask for better governance and tough review in EU Human Brain Project. Science story | Follow @EmilyMFierce

> Lilly partners with China's Yabao on diabetes drug. Item

> Boehringer's 'breakthrough' cancer drug comes through in Phase II. Report

> Versant close to capping $300M fund to foster next-gen biotechs. Article

> Novartis' leading CAR-T cancer therapy gains 'breakthrough' status at the FDA. Story

Biotech Research News

> Schizophrenia-linked genetic variation causes abnormal brain cell development. More

> Blocking cell migration could stop cancer spread. Article

> Technique regrows corneas in mice from adult human stem cells. Story

> Chemical switch could be drug target for neurodegenerative disease. More

> AstraZeneca, MRC Technology renew preclinical pact. Item

Pharma Manufacturing News

> Cipla plans U.K. investment as Indian drugmakers await economic reforms. More

> Ingredient price hikes prompt Express Scripts to slash coverage of compounded drugs. Story

> Novo A/S-owned Xellia snaps up Fresenius vial plant to expand in U.S. Report

> Hospira completes Orchid plant takeover to boost API supply security. Item

> Ingredient price hikes prompt Express Scripts to slash coverage of compounded drugs. Story

> Health Canada gives GSK 30 days to show how it will fix its vaccine plant. Article

And Finally... Malaysia's state-owned FELDA plans a $300 million listing on the "life sciences-friendly" Nasdaq as it prepares to bring plant-based drugs to the U.S. Story